Bangladesh Drugmakers See Limited Gains From US Pharma Tariff Exemption Amid Capacity And Regulatory Hurdles
Bangladesh's pharmaceutical industry may see some opportunities from the latest US tariff adjustment that grants zero ad valorem tariff on certain pharmaceutical products from eligible jurisdictions, but industry leaders say immediate benefits are limited because local manufacturers do not produce the highly specialised drugs covered.